Texas Attorney General Ken Paxton is looking to protect Texans' genetic data with action filed this week in ongoing 23andMe ...

Japan’s Nippon Steel has completed its purchase of U.S. Steel after reaching a national-security agreement with the White ...

Last month, Regeneron had agreed to buy the firm for $256 million, beating an earlier $146 million bid from Wojcicki and the ...

This corrects the date that the BMO Capital note was published. Shares of Regeneron Pharmaceuticals Inc. were having their worst day in more than a decade on Friday after a shocking failure in a ...

Regeneron Pharmaceuticals (NASDAQ:REGN) shares witnessed a notable 19% decline on Friday, May 30, in the wake of the unexpected failure of itepekimab, its chronic obstructive pulmonary disease ...

Regeneron Pharmaceuticals (REGN) has been in a persistent downtrend for over 280 days. The stock is currently in the 10th Phase of its 18-Phase Adhishthana Cycle, our proprietary cyclical framework.

Regeneron Pharmaceuticals (REGN) shares sank in Friday trading after the company published disappointing drug trial results for a treatment on a condition called smoker's lungs. The drug was co ...

Continue » Regeneron's purchase is still subject to court approval. If it gets a green light, as expected, the company could gain access to genetic data from more than 15 million 23andMe ...

Shares of biotech company Regeneron (NASDAQ:REGN) fell 19% in the afternoon session after the company announced mixed results from its Phase 3 trials for itepekimab, an experimental drug for ...

Regeneron Pharmaceuticals has entered a strategic licensing agreement with Hansoh Pharmaceuticals to secure exclusive rights for the clinical development and commercialization of HS-20094, a dual ...

Regeneron said Monday it will “prioritize the privacy, security and ethical use” of the personal DNA data from about 15 million people in a $256 million deal to acquire assets of bankrupt ...